Literature DB >> 6624436

Clinical appearance and outcome in mumps encephalitis in children.

M Koskiniemi, M Donner, O Pettay.   

Abstract

Forty-one patients with mumps encephalitis examined at the Department of Paediatrics, University of Helsinki, during the period Jan. 1, 1968, to Dec. 31, 1980, were reviewed with special reference to clinical appearance and outcome. The ratio of males to females was 4:1 and the age range 1.2 to 13.7 years. The clinical findings were high fever greater than or equal to 39 degrees C in 83.0%), impairment of locomotion and balance (36.6%), seizures (24.4%), psychic disorders (22.0%), depressed level of consciousness (19.5%), vertigo (12.9%) and/or gastric pains (12.9%). One patient with congenital toxoplasma and cytomegalovirus infections died. On leaving the hospital eight were still ataxic, one of these was not able to speak and two had difficulties in concentration. One patient was transferred to another hospital because of psychosis. At the follow-up examination 4 to 24 months after the onset of the disease two patients were ataxic and seven suffered from behavioural disturbances. Electroencephalography (12.2% of all and 25% of examined patients) showed generalized slow wave disturbance at follow-up in six patients and borderline disturbances in eight.

Entities:  

Mesh:

Year:  1983        PMID: 6624436     DOI: 10.1111/j.1651-2227.1983.tb09778.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  14 in total

1.  Mumps Associated Acute Motor Axonal Polyneuropathy.

Authors:  Siyaram Didel; Renu Suthar; Debasish Sahoo; Mini P Singh; Jitendra K Sahu
Journal:  Indian J Pediatr       Date:  2017-04-24       Impact factor: 1.967

2.  Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases.

Authors:  G P Poggio; C Rodriguez; D Cisterna; M C Freire; J Cello
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Clinical predictors of outcome in encephalitis.

Authors:  C R Kennedy; S W Duffy; R Smith; R O Robinson
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

4.  MRI of mumps encephalitis: comparison with CT evaluation.

Authors:  R W Tarr; K M Edwards; R M Kessler; M V Kulkarni
Journal:  Pediatr Radiol       Date:  1987

5.  Mumps encephalitis with bilateral hippocampal lesions preceding parotitis.

Authors:  Yong Chuan Chee; Beng Hooi Ong
Journal:  Neurol Clin Pract       Date:  2019-12

6.  Cerebellar encephalitis in adults.

Authors:  A Alfaro
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

Review 7.  Management of cerebral infection.

Authors:  M Anderson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

8.  Epidemiology of a mumps outbreak in a highly vaccinated island population and use of a third dose of measles-mumps-rubella vaccine for outbreak control--Guam 2009 to 2010.

Authors:  George E Nelson; Annette Aguon; Engracia Valencia; Rita Oliva; Michele Leon Guerrero; Richard Reyes; Anna Lizama; Daryl Diras; Annakutty Mathew; E Jessica Camacho; Moryne-Nicole Monforte; Tai-Ho Chen; Abdirahman Mahamud; Preeta K Kutty; Carole Hickman; William J Bellini; Jane F Seward; Kathleen Gallagher; Amy Parker Fiebelkorn
Journal:  Pediatr Infect Dis J       Date:  2013-04       Impact factor: 2.129

9.  Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype.

Authors:  Steven A Rubin; Georgios Amexis; Mikhail Pletnikov; Zongqi Li; Jacqueline Vanderzanden; Jeremy Mauldin; Christian Sauder; Tahir Malik; Konstantin Chumakov; Kathryn M Carbone
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 10.  Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management.

Authors:  Marie Studahl; Lars Lindquist; Britt-Marie Eriksson; Göran Günther; Malin Bengner; Elisabeth Franzen-Röhl; Jan Fohlman; Tomas Bergström; Elisabeth Aurelius
Journal:  Drugs       Date:  2013-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.